News
Celldex Therapeutics Aktie: Droht nun Stagnation?
Die Celldex Therapeutics Aktie verzeichnete am 12. März 2025 eine deutliche Erholung mit einem Plus von 4,81 Prozent auf 20,50 USD im Vergleich zum Vortag. Diese positive Entwicklung steht im
Pfizer Stock: Shares Drop Despite Cancer Drug Progress
Pfizer's stock fell 1.7% to $26.20 in Tuesday afternoon trading on the New York Stock Exchange, despite the company announcing promising results from a key clinical trial. The decline came amid
Pfizer Stock: Shares Drop Despite Cancer Drug Progress
Pfizer's stock fell 1.7% to $26.20 in Tuesday afternoon trading on the New York Stock Exchange, despite the company announcing promising results from a key clinical trial. The decline came amid
Bristol-Myers Squibb Stock: $286M Acquisition Targets Cancer Therapy
Bristol-Myers Squibb has announced a definitive agreement to acquire biotechnology company 2seventy bio for $5.00 per share in an all-cash transaction. The deal values 2seventy bio at approximately
Cerus Stock: Insider Sales Amid Positive Business Growth
Cerus Corporation's leadership team has recently executed several stock sales, drawing investor attention as the transactions occurred while shares traded near their 52-week low. The company's CEO
Align Stock: AI Diagnostic Software Launches Amid Financial Challenges
Align Technology, a digital dentistry leader valued at $12.1 billion, has announced the European Union and UK launch of its AI-powered "Align X-ray Insights" diagnostic software. The cloud-based
Align Stock: AI Diagnostic Software Launches Amid Financial Challenges
Align Technology, a digital dentistry leader valued at $12.1 billion, has announced the European Union and UK launch of its AI-powered "Align X-ray Insights" diagnostic software. The cloud-based
Align Stock: AI Diagnostic Software Launches Amid Financial Challenges
Align Technology, a digital dentistry leader valued at $12.1 billion, has announced the European Union and UK launch of its AI-powered "Align X-ray Insights" diagnostic software. The cloud-based
Johnson & Johnson Stock: New Cancer and Colitis Treatments Show Promise
Johnson & Johnson's stock could receive significant momentum following positive developments in multiple therapeutic areas. The company recently secured approval from Health Canada for a combination
Johnson & Johnson Stock: New Cancer and Colitis Treatments Show Promise
Johnson & Johnson's stock could receive significant momentum following positive developments in multiple therapeutic areas. The company recently secured approval from Health Canada for a combination
If You Could Only Hold 3 Investments for Life, Consider These
Warren Buffett, who is known to own “forever stocks,” has famously quipped that if you aren’t willing to own a stock for 10 years, you shouldn’t own it for even 10 minutes.
This idea prompts a
BioNTech veröffentlicht Ergebnisse für das vierte Quartal und das Geschäftsjahr 2024 sowie Informationen zur Geschäftsentwicklung
- Onkologie-Pipeline weiterentwickelt mit mehr als 20 aktiven klinischen Phase-2- und Phase-3-Studien mit strategischem Fokus auf zwei tumorübergreifende (Pan-Tumor-)Programme:
BioNTech veröffentlicht Ergebnisse für das vierte Quartal und das Geschäftsjahr 2024 sowie Informationen zur Geschäftsentwicklung
- Onkologie-Pipeline weiterentwickelt mit mehr als 20 aktiven klinischen Phase-2- und Phase-3-Studien mit strategischem Fokus auf zwei tumorübergreifende (Pan-Tumor-)Programme:
Institutional Investors Bet $1B on These 4 Stocks—Should You?
Institutional investing is a key measure that retail investors can use to gauge market sentiment on an individual stock or asset. Hedge funds, advisors and other institutional investors employ
Bayer AG Stock: Shares Plunge on Capital Raise Concerns
Bayer AG's stock tumbled significantly on Friday, closing down 6.46 percent at €23.25 after the company announced plans to seek shareholder approval for a substantial capital authorization. At the
Bayer AG Stock: Shares Plunge on Capital Raise Concerns
Bayer AG's stock tumbled significantly on Friday, closing down 6.46 percent at €23.25 after the company announced plans to seek shareholder approval for a substantial capital authorization. At the
Merck Stock: Technical Stabilization Emerges After Slump
Darmstadt-based pharmaceutical and technology company Merck is showing initial signs of technical stabilization following an extended period of weakness. Currently trading at approximately €135, the
Eli Lilly Stock: Skin Drug Shows Strong Long-term Results
Eli Lilly has reported significant progress with its medication Ebglyss for moderate to severe atopic dermatitis. At the American Academy of Dermatology annual meeting in Orlando, the company
BeiGene Stock: Top Executives Sell Shares Near Record High
BeiGene, a leading pharmaceutical company with strong growth potential, is experiencing significant share sales by its top management. CEO John Oyler has divested shares worth approximately €25
Cytokinetics Stock: Executives Sell Shares Despite Growth Outlook
Cytokinetics Inc. has recently seen multiple executives selling portions of their stock holdings, all reportedly to cover tax obligations related to Restricted Stock Unit transfers. CEO Robert Blum
Halozyme Therapeutics Aktie: Optimismus im Aufbruch!
Die Halozyme Therapeutics Aktie verzeichnete am 8. März 2025 einen weiteren Kursanstieg von 1,38 Prozent und notiert aktuell bei 60,98 USD. Der Biotechnologiewert setzt damit seinen positiven Trend
Blueprint Medicines Stock: Executives Sell Shares Amid Growth
Blueprint Medicines, a biopharmaceutical company headquartered in Cambridge, Massachusetts, recently reported several significant stock transactions by its leadership team. Multiple executives sold
EQS-HV: Bayer Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 25.04.2025 in Virtuell/Leverkusen mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
EQS-HV: Bayer Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 25.04.2025 in Virtuell/Leverkusen mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
Pfizer Stock: Nearing 52-Week Lows Amid Challenges
Pfizer's stock currently faces a challenging market position, trading precariously close to its 52-week lows. The shares recently showed minimal recovery, rising just 0.2 percent to $25.99 in New